RecruitingPhase 1NCT06270316
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UniQure Biopharma B.V.
- Principal Investigator
- Arian Pano, MD, MPHClinical Development and Progam Lead, uniQure Biopharma, B.V.
- Intervention
- AMT-191(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-50 years · MALE
- Timeline
- 2024 – 2027
Study locations (8)
- The Kirklin Clinic Of university of Alabama Birmingham Hospital, Birmingham, Alabama, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- MHealth Fairview University of Minnesota Medical Center East Bank, Minneapolis, Minnesota, United States
- NYC Health + Hospitals/Metropolitan, New York, New York, United States
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Utah, Clinical and Translational Sciences Institute, Salt Lake City, Utah, United States
- Lysosomal & Rare Disorders Research and Treatment Center, Inc, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06270316 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.